Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Graeff

Showing results (171-180 of 206) with videos related to

Pageof 21
Sort By:
International Journal of Oncology|March 24, 1999
HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancerN Harbeck, J S Ross, S Yurdseven, et al.
FEBS Letters|February 3, 1992
Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin LL Goretzki, M Schmitt, K Mann, et al.
The Journal of Biological Chemistry|March 15, 1991
Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA)H Kobayashi, M Schmitt, L Goretzki, et al.
Cancer Research|June 15, 1988
Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stromaO Wilhelm, R Hafter, E Coppenrath, et al.
Histopathology|September 1, 1991
Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectumC F Sier, C Fellbaum, H W Verspaget, et al.
Thrombosis and Haemostasis|July 1, 1997
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapyM Schmitt, N Harbeck, C Thomssen, et al.
Geburtshilfe Und Frauenheilkunde|September 1, 1982
[Perioperative short-term prophylaxis with antibiotics in caesarean section]H H Warnecke, H Graeff, H K Selbmann, et al.
British Journal of Cancer|July 17, 1999
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-upN Harbeck, P Dettmar, C Thomssen, et al.
Journal of Obstetrics and Gynaecology (Tokyo, Japan)|April 1, 1995
Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasisM Schmitt, O Wilhelm, F Jänicke, et al.
Anticancer Research|August 15, 1998
Prognostic impact of tumor biological factors on survival in node-negative breast cancerN Harbeck, P Dettmar, C Thomssen, et al.
Pageof 21

Showing results (171-180 of 206) with videos related to

Sort By:
Pageof 21
International Journal of Oncology|March 24, 1999
HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancerN Harbeck, J S Ross, S Yurdseven, et al.
FEBS Letters|February 3, 1992
Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin LL Goretzki, M Schmitt, K Mann, et al.
The Journal of Biological Chemistry|March 15, 1991
Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA)H Kobayashi, M Schmitt, L Goretzki, et al.
Cancer Research|June 15, 1988
Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stromaO Wilhelm, R Hafter, E Coppenrath, et al.
Histopathology|September 1, 1991
Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectumC F Sier, C Fellbaum, H W Verspaget, et al.
Thrombosis and Haemostasis|July 1, 1997
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapyM Schmitt, N Harbeck, C Thomssen, et al.
Geburtshilfe Und Frauenheilkunde|September 1, 1982
[Perioperative short-term prophylaxis with antibiotics in caesarean section]H H Warnecke, H Graeff, H K Selbmann, et al.
British Journal of Cancer|July 17, 1999
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-upN Harbeck, P Dettmar, C Thomssen, et al.
Journal of Obstetrics and Gynaecology (Tokyo, Japan)|April 1, 1995
Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasisM Schmitt, O Wilhelm, F Jänicke, et al.
Anticancer Research|August 15, 1998
Prognostic impact of tumor biological factors on survival in node-negative breast cancerN Harbeck, P Dettmar, C Thomssen, et al.
Pageof 21